Graft-versus-host disease treatment: predictors of survival.

[1]  M. MacMillan,et al.  The best endpoint for acute GVHD treatment trials. , 2010, Blood.

[2]  Thomas M Braun,et al.  Elafin Is a Biomarker of Graft-Versus-Host Disease of the Skin , 2008, Science Translational Medicine.

[3]  D. Massi,et al.  Increase in FOXP3+ regulatory T cells in GVHD skin biopsies is associated with lower disease severity and treatment response. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  M. Pasquini,et al.  Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. , 2009, Blood.

[5]  O. Shpilberg,et al.  Prophylaxis regimens for GVHD: systematic review and meta-analysis , 2009, Bone Marrow Transplantation.

[6]  Thomas M Braun,et al.  A biomarker panel for acute graft-versus-host disease. , 2009, Blood.

[7]  E. Holler,et al.  Graft-versus-host disease , 2009, The Lancet.

[8]  Paul J. Martin,et al.  Study design and endpoints in graft-versus-host disease. , 2008, Best practice & research. Clinical haematology.

[9]  M. Pasquini.  Impact of graft-versus-host disease on survival. , 2008, Best practice & research. Clinical haematology.

[10]  W. Leisenring,et al.  An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. , 2006, Blood.

[11]  N. Chao,et al.  Prophylaxis and treatment of acute graft-versus-host disease. , 2006, Seminars in hematology.

[12]  M. Boccadoro,et al.  Corticosteroids can reverse severe imatinib-induced hepatotoxicity. , 2006, Haematologica.

[13]  P. Ljungman,et al.  Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. , 2006, Haematologica.

[14]  J. Klein,et al.  Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. , 2005, Blood.

[15]  Allen R. Chen,et al.  Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  M. Flowers,et al.  Diagnosis and clinical management of chronic graft-versus-host disease , 2004, International journal of hematology.

[17]  M. Flowers,et al.  Chronic graft-versus-host disease. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  J. Wagner,et al.  Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  J. Wingard.  Fungal infections after bone marrow transplant. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.